< Previous page
All
Airlines/Aviation
Auto
Maritime/Shipbuilding
Transportation
Computer Hardware
Computer Networks
Computer Software
Computer/Electronics
Electronic Commerce
Electronic Components
High Tech Security
Internet Technology
Peripherals
Semiconductors
Electronics Gaming
Consumer Electronics
Mobile Entertainment
Multimedia/Online/Internet
Telecommunications
Household/Consumer/Cosmetics
Retail
Supermarkets
Toys
Alternative Energies
Chemical
Mining/Metals
Oil/Energy
Environmental Products & Services
Green Technology
Art
Cosmetics & Personal Care
Entertainment
Fashion
Film & Motion Picture
Jewelry
Banking/Financial Service
Insurance
Workforce Management/Human Resources
Education
Higher Education
Biotechnology
Health Care/Hospital
Infectious Disease Control
Medical Equipment
Medical/Pharmaceuticals
Agriculture
Machinery
Paper/Forest Products/Containers
Textiles
Domestic policy
Legal issues
Sports
Hotels and Resorts
Leisure/Travel/Hotels
Travel
Restaurants
Beer, Wine & Spirits
Beverages
Non-Alcoholic Beverages
Food/Beverages
Advertising
Books
Music
Publishing/Information Service
Television
Trade show news
Real Estate
Construction/Building
Furniture & Furnishings
|
Title only
|
Print
Next page >
88IV - PR Newswire Asia's news
5
Innovent Announces Taletrectinib(ROS1 Inhibitor)Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting
SAN FRANCISCO and SUZHOU, China , June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures ...
2024-06-02T
Biotechnology
Health Care/Hospital
Medical/Pharmaceuticals
Jacobio Pharma Presents SHP2 Plus KRAS G12C Data at ASCO
BEIJING and SHANGHAI and CHICAGO , June 2, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, presented updated data of a KRAS G12C ...
2024-06-02T
Banking/Financial Service
Health Care/Hospital
Medical/Pharmaceuticals
CStone Announces European Medicine Agency CHMP Recommends Approval of Cejemly® (sugemalimab, anti-PD-L1) as First-Line Treatment for NSCLC
EMA CHMP recommendation is based on the results of a Phase 3 clinical trial (GEMSTONE-302) demonstrating significant progression-free survival (PFS) and overall survival (OS) benefits of sugemalimab in ...
2024-06-02T
Health Care/Hospital
Medical/Pharmaceuticals
Innovent Presents Phase 1 Clinical Data of First-in-class PD-1/IL-2α Bispecific Antibody Fusion Protein (IBI363) in Melanoma, Colorectal Cancer and other Solid Tumors at the 2024 ASCO Annual Meeting
SAN FRANCISCO , U.S. and SUZHOU, China , June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures ...
2024-06-02T
Biotechnology
Health Care/Hospital
Medical/Pharmaceuticals
Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib(ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting
SAN FRANCISCO , U.S. and SUZHOU, China , June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures ...
2024-06-02T
Biotechnology
Health Care/Hospital
Medical/Pharmaceuticals
GenFleet Therapeutics Announces Efficacy & Safety Result from Phase II Trial for First-line NSCLC Treatment in KROCUS Study, fulzerasib (KRAS G12C Inhibitor) in Combination with cetuximab, in a Late-breaking Abstract at the Oral Presentation of 2024 ASCO Annual Meeting
SHANGHAI and CHICAGO , June 2, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the ...
2024-06-02T
Biotechnology
Health Care/Hospital
Medical/Pharmaceuticals
Immunofoco Biotech to Unveil Solid Tumor CAR-T Programs Clinical Trial Data at 2024 ASCO Meeting
CHICAGO , June 2, 2024 /PRNewswire/ -- On June 1 st , 2024, Immunofoco Biotech, a company dedicated to developing cell therapy products for solid tumors, announced that the clinical research data for ...
2024-06-02T
Biotechnology
Health Care/Hospital
Medical/Pharmaceuticals
Z Grills Announces Unprecedented "Buy 1, Get 10 Grills" Promotion, Unlocking a Lifetime of Easier Grilling!
ONTARIO, Calif. , June 1, 2024 /PRNewswire/ -- Mark your calendars, grill masters! Z Grills, the innovator in premium wood pellet grills, is sizzling up summer with a groundbreaking promotion that's ...
2024-06-01T
Food/Beverages
Household/Consumer/Cosmetics
Retail
Tag along with Jason in Zhengzhou: Experiencing Kung Fu at the Shaolin Temple
BEIJING , May 30, 2024 /PRNewswire/ -- This is a report from China.org.cn about the Shaolin Temple: ...
2024-06-01T
Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca® Mouse
BOSTON , June 1, 2024 /PRNewswire/ -- Immunocan announces significant progress in the construction of its alpaca-derived nanobody discovery platform, ImmuAlpaca ® mouse. The IGH-VDJ genes in ...
2024-06-01T
Biotechnology
Health Care/Hospital
Medical/Pharmaceuticals
Next page >
Disclaimer :
In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.